Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Danielle Broadway LOS ANGELES, Aug 11 (Reuters) - The culturally diverse girl group KATSEYE,…
By Danielle Broadway LOS ANGELES, Aug 11 (Reuters) - The culturally diverse girl group KATSEYE,…
Don't sit there sweating in your smart suit when temperatures are soaring outside. Linen is…
By Danielle Kaye and Joyce Zhou NEW YORK/HONG KONG, Aug 11 (Reuters) - Taylor Swift's…
Aug 11 (Reuters) - Disney said on Tuesday it had signed a multi-year deal to…
Aug 11 (Reuters) - Disney said on Tuesday it had signed a multi-year deal to…